NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Neumora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.47−0.00 (-0.80%)
Close on Oct 19, 2026
- Market cap
- $87.03M
- P/E (TTM)
- –
- Dividend yield
- –
Neumora Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Market Cap | $88.31M | $166.30M |
| Enterprise Value | $84.39M | $88.19M |
| PB Ratio | 1.98 | 2.03 |
| P/TBV Ratio | 1.98 | 2.29 |
Income (trailing twelve months)
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$211.23M | -$21.40M |
| Pretax Income | -$212.72M | -$14.34M |
| Net Income | -$212.75M | -$22.46M |
| EBITDA | -$211.19M | -$16.91M |
| EPS (Diluted) | -$1.23 | -$0.83 |
Returns
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -187.1% | -53.2% |
| Return on Assets (ROA) | -121.9% | -40.9% |
| Return on Invested Capital (ROIC) | -736.1% | -32.4% |
| Return on Capital Employed (ROCE) | -216.7% | -38.1% |
Balance sheet
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $116.83M | $61.43M |
| Total Debt | $112.91M | $118.52M |
| Net Cash (Debt) | $3.92M | $15.35M |
| Net Cash Per Share | $0.02 | $0.66 |
| Equity (Book Value) | $44.52M | $49.09M |
| Book Value Per Share | $0.24 | $1.37 |
| Tangible Book Value | $44.52M | $23.52M |
| Working Capital | $97.10M | $76.81M |
Financial position
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.50 | 3.34 |
| Quick Ratio | 4.21 | 2.44 |
| Debt / Equity | 2.54 | 0.52 |
| Interest Coverage | -47.62 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$180.52M | -$12.35M |
Efficiency
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.22M | -$703.34K |
| Employee Count | 96 | 74 |
Dividends and yields
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -240.9% | -23.3% |
Shares
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 187,896,000 | 58,127,000 |
| Shares Change (YoY) | 8.04% | 10.9% |
| Float | 144,992,000 | 49,136,700 |
| Shares Held by Insiders | 22.8% | 11.6% |
| Shares Held by Institutions | 40.4% | 59.4% |
Taxes
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Income Tax | $30.00K | $79.87K |
Scores
| Measure | Neumora Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -18.29 | -0.22 |
| Piotroski F-Score | 0 | 4 |
Calculated by StockData from Neumora Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.